How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
Leemore Dafny,
Kate Ho and
Edward Kong
No 29735, NBER Working Papers from National Bureau of Economic Research, Inc
Abstract:
We estimate the causal effects of drug copayment coupons, which reduce consumer cost-sharing for branded prescription drugs, on net-of-rebate price and quantities sold. Focusing on drugs without generic substitutes, we show that coupon introductions increase quantity sold by 23-25% for the commercial segment relative to Medicare Advantage, where coupons are banned. To quantify the resulting equilibrium price effects, we estimate a discrete choice model of demand for multiple sclerosis drugs and simulate a model of drug price negotiations. We estimate that net-of-rebate prices are 8% higher due to the availability of coupons for most of these drugs.
JEL-codes: I11 I13 L13 (search for similar items in EconPapers)
Date: 2022-02
New Economics Papers: this item is included in nep-ban, nep-com, nep-hea, nep-ias and nep-ind
Note: EH IO
References: Add references at CitEc
Citations: View citations in EconPapers (2)
Published as Leemore Dafny & Kate Ho & Edward Kong, 2024. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?," American Economic Journal: Economic Policy, vol 16(3), pages 314-346.
Downloads: (external link)
http://www.nber.org/papers/w29735.pdf (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:29735
Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w29735
Access Statistics for this paper
More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().